Glaxosmithkline Plc (GSK) 42.85 $GSK
The Global Defenders
Eric Parnell, CFA - at Seeking Alpha - Wed Dec 24, 12:25AM CST
BUD: 115.51 (+0.09), EIS: 46.92 (-0.19), UN: 39.92 (+0.05), UL: 41.49 (+0.09), EWN: 24.48 (+0.15), GSK: 42.85 (+0.11), XLU: 47.97 (+0.87), EWL: 32.34 (+0.14), DEO: 116.91 (+0.98), EWK: 16.58 (+0.08), XLV: 68.64 (+0.50), XLP: 49.38 (-0.05), IYZ: 29.52 (-0.18), SPY: 207.77 (+0.02), RDS.A: 68.42 (-0.31), NVO: 43.80 (+1.08), AZN: 70.44 (+0.26), ENZL: 39.52 (+0.22), EWU: 18.39 (+0.15), TEVA: 57.09 (+0.33), ACWX: 43.59 (+0.24), EDEN: 48.09 (+0.18), NGG: 72.20 (+1.11), NVS: 93.91 (+0.66)
Look for Shares of GlaxoSmithKline to Potentially Rebound after Yesterday's 1.61% Sell Off
Comtex SmarTrend(R) - Tue Dec 23, 4:26PM CST
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $42.62 to a high of $43.31. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $42.66 on volume of 4.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GSK: 42.85 (+0.11)
GlaxoSmithKline Set to Possibly Rebound After Yesterday's Selloff of 1.61%
Comtex SmarTrend(R) - Tue Dec 23, 4:25PM CST
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $42.62 to a high of $43.31. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $42.66 on volume of 4.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GSK: 42.85 (+0.11)
BioMarin CEO Sees Big Future For Prosensa Drug
at Investor's Business Daily - Tue Dec 23, 3:11PM CST
BioMarin Pharmaceuticals raised a few eyebrows last month when it announced its latest buyout. BioMarin (BMRN) agreed to pay $680 million upfront for Prosensa Holding (RNA), a Dutch biotech developing a drug for Duchenne muscular dystrophy called...
BMRN: 88.18 (+0.89), RNA: 18.76 (+0.10), PTCT: 51.66 (+0.76), GSK: 42.85 (+0.11)
Roivant Acquires SB742457 From GlaxoSmithKline
GlobeNewswire - Tue Dec 23, 9:29AM CST
-Roivant intends to commence Phase 3 clinical trials in Alzheimer's disease in 2015-
GSK: 42.85 (+0.11)
3 Clinical Stage Biotech Stocks That Should Be on Your Watchlist in 2015
Motley Fool Staff - Motley Fool - Tue Dec 23, 6:07AM CST
Source: Celgene Corp Biotech stocks are notorious for their stratospheric gains and subterranean losses, especially clinical stage biotech stocks that develop promising, yet unproven, next-generation drugs. Those emerging biotech stocks may offer...
BLUE: 88.76 (+3.23), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), NVS: 93.91 (+0.66), CELG: 109.60 (+3.48), FPRX: 26.12 (+0.07), EXEL: 1.29 (-0.01)
Glaxo submits sNDA for Promacta expanded label
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 10:48AM CST
LGND: 51.79 (+1.22), GSK: 42.85 (+0.11)
3 Drugmakers Facing a Pivotal 2015
George Budwell, The Motley Fool - Motley Fool - Mon Dec 22, 10:41AM CST
Source: www.bio.org Pharmaceutical companies have been some of the best performing stocks lately due to the confluence of an aging U.S. population and new regulatory avenues within the Food and Drug Administration that have led to an uptick in drug...
BIIB: 340.89 (+5.13), ISIS: 59.49 (+1.88), GWPH: 68.08 (+1.82), AZN: 70.44 (+0.26), IBB: 299.80 (+5.12), PTCT: 51.66 (+0.76), GSK: 42.85 (+0.11)
Overvalued Bonds Or Would You Buy Stocks With A PE Of 100?
Seeking Early Retirement - at Seeking Alpha - Mon Dec 22, 8:31AM CST
BTI: 110.32 (+1.08), IEF: 105.25 (-0.08), COP: 70.13 (-0.92), MO: 50.36 (-0.17), GSK: 42.85 (+0.11), VOD: 34.65 (-0.05), PM: 83.15 (-0.15), T: 33.96 (-0.07), SPY: 207.77 (+0.02), RDS.A: 68.42 (-0.31), DIA: 180.03 (unch), BP: 38.95 (-0.17), SNY: 46.35 (+0.50), CVX: 113.47 (-0.48), VZ: 47.67 (unch)
Ligand Partner GlaxoSmithKline Announces US Regulatory Submission Seeking Additional Indication for Promacta(R)
Business Wire - Mon Dec 22, 8:20AM CST
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that its partner GlaxoSmithKline (GSK) plc reported the submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration for eltrombopag (Promacta), seeking an additional indication in pediatric patients six years old and older with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.
LGND: 51.79 (+1.22), GSK: 42.85 (+0.11)
The Most Disappointing Clinical Failures in 2014
Motley Fool Staff - Motley Fool - Sun Dec 21, 6:32PM CST
Since roughly 90% of all clinical trials end in a failure, it isn't too shocking that 2014 boasted its fair share of clinical trial disappointments. But while failure is common and expected in the industry, some defeats were more disappointing than...
MDVN: 99.23 (+1.23), JNJ: 104.59 (+0.31), AZN: 70.44 (+0.26), PFE: 31.42 (-0.03), AMGN: 160.67 (+3.15), GSK: 42.85 (+0.11), EXEL: 1.29 (-0.01)
Exciting News: A Game-Changing Shingles Vaccine Could Be On Its Way
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 21, 6:14AM CST
Source: GlaxoSmithKline plc GlaxoSmithKline reported late stage trial results for a promising new vaccine for the prevention of shingles that could help millions of people, and in the process win away sales from Merck & Co .'s shingles...
PFE: 31.42 (-0.03), MRK: 57.46 (+0.25), GSK: 42.85 (+0.11)
Tax-Loss Selling: 1 Stock We'd Be Glad to Sell Right Now
Motley Fool Staff - Motley Fool - Sat Dec 20, 4:05PM CST
The end of the year is a good time to unload any stocks that are sinking your portfolio. With 2014 rapidly coming to an end, many investors are selling off some of their losing investments to reap the tax benefits. Keep in mind that it's not a...
CHK: 19.84 (-0.45), GSK: 42.85 (+0.11), PSEC: 8.59 (-0.02), NVS: 93.91 (+0.66)
The Early Retiree Portfolio For 2015
Early Retiree - at Seeking Alpha - Fri Dec 19, 5:17PM CST
CBI: 41.94 (-0.17), WAIR: 14.20 (unch), VRX: 140.33 (-0.22), DVA: 76.06 (+0.07), IBM: 161.82 (-0.42), THRX: 14.55 (+0.22), TBPH: 14.84 (+0.20), GSK: 42.85 (+0.11), UG: 19.75 (-0.11)
Agenus Jumps on Positive Data from Shingles Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 3:09PM CST
Shares of Agenus Inc. (AGEN) jumped after its partner GlaxoSmithKline (GSK) announced encouraging results on HZ/su.
AGEN: 3.85 (unch), BIIB: 340.89 (+5.13), AMGN: 160.67 (+3.15), GSK: 42.85 (+0.11)
Seeking Alpha's Biotech Weekly: A Merck Purchase, Spectacular Auspex, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Dec 19, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. What should the Seeking Alpha community be reading and writing about? Please leave...
SPHS: 0.46 (+0.02), ASPX: 49.93 (-0.10), MDVN: 99.23 (+1.23), CYCC: 0.69 (+0.01), OPK: 9.63 (+0.21), NLNK: 39.08 (+1.36), JUNO: 39.99 (+2.71), REGN: 400.12 (+6.07), MYGN: 36.50 (+0.28), PFE: 31.42 (-0.03), IMGN: 5.90 (+0.13), AMGN: 160.67 (+3.15), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), BLRX: 1.68 (-0.01), OREX: 5.98 (+0.01), DVA: 76.06 (+0.07), BLCM: 19.30 (+0.18), CBST: 100.29 (-0.09), GILD: 91.29 (+1.84), GERN: 3.06 (+0.05), MRK: 57.46 (+0.25), NVS: 93.91 (+0.66)
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 340.89 (+5.13), VRX: 140.33 (-0.22), QLTI: 3.72 (+0.08), CTRX: 51.83 (+0.14), BCRX: 11.83 (+0.76), ACT: 254.20 (-1.68), MDT: 74.08 (+0.31), TKMR: 13.97 (+0.14), NEPT: 1.88 (+0.03), BSX: 13.13 (+0.07), AGN: 210.12 (+0.95), CMRX: 36.80 (+0.70), ALNY: 93.52 (+0.97), SRPT: 13.88 (+0.47), SHPG: 209.29 (+0.07), NLNK: 39.08 (+1.36), SNY: 46.35 (+0.50), MSLI: 1.67 (+0.02), NVCN: 6.60 (unch), CRME: 8.56 (+0.06), EBS: 27.64 (+1.28), GSK: 42.85 (+0.11), CELG: 109.60 (+3.48), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), NVDQ: 16.90 (+0.55), NVS: 93.91 (+0.66)
Strength Seen in Agenus (AGEN): Stock Soars 17.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 8:46AM CST
Agenus (AGEN) was a big mover last session, with shares rising over 17% on the day.
AGEN: 3.85 (unch), GSK: 42.85 (+0.11)
Factors Moving Markets: Complementary Research on GlaxoSmithKline, Cintas, Deere, Thermo Fisher and Pfizer
PR Newswire - Fri Dec 19, 8:10AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including GlaxoSmithKline (NYSE: GSK), Cintas (NASDAQ: CTAS), Deere (NYSE: DE), Thermo Fisher (NYSE: TMO), and Pfizer (NYSE: PFE). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
CTAS: 79.86 (+0.22), TMO: 126.79 (+0.13), PFE: 31.42 (-0.03), DE: 90.26 (-0.59), GSK: 42.85 (+0.11)
Acne Vulgaris - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/86w8nv/acne_vulgaris) has announced the addition of the "Acne Vulgaris - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acne Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acne Vulgaris and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acne Vulgaris - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acne Vulgaris pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Advancell - Allergan - AndroScience - AntiCancer - Ausio Pharmaceuticals - Biomar Microbial - Boehringer Ingelheim - Braintree Laboratories - Celtaxsys - Cosmo Pharmaceuticals - Cutanea Life Sciences - Delenex Therapeutics - Deltanoid Pharmaceuticals - Dermira - ELORAC - Ensoltek - Foamix - Galderma - GlaxoSmithKline - Kasiak Research - Maruho - OrigImm - Phosphagenics - Photocure - Provectus Biopharmaceuticals - RestorGenex Corporation - Thesan Pharmaceuticals - Toyama Chemical - Valeant Pharmaceuticals International - XBiotech USA - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/86...e_vulgaris
PVCT: 0.85 (-0.02), AGN: 210.12 (+0.95), GSK: 42.85 (+0.11), XOMA: 3.68 (+0.11), VRX.TO: 162.98 (-0.62)
The Global Defenders
Eric Parnell, CFA - at Seeking Alpha - Wed Dec 24, 12:25AM CST
BUD: 115.51 (+0.09), EIS: 46.92 (-0.19), UN: 39.92 (+0.05), UL: 41.49 (+0.09), EWN: 24.48 (+0.15), GSK: 42.85 (+0.11), XLU: 47.97 (+0.87), EWL: 32.34 (+0.14), DEO: 116.91 (+0.98), EWK: 16.58 (+0.08), XLV: 68.64 (+0.50), XLP: 49.38 (-0.05), IYZ: 29.52 (-0.18), SPY: 207.77 (+0.02), RDS.A: 68.42 (-0.31), NVO: 43.80 (+1.08), AZN: 70.44 (+0.26), ENZL: 39.52 (+0.22), EWU: 18.39 (+0.15), TEVA: 57.09 (+0.33), ACWX: 43.59 (+0.24), EDEN: 48.09 (+0.18), NGG: 72.20 (+1.11), NVS: 93.91 (+0.66)
Look for Shares of GlaxoSmithKline to Potentially Rebound after Yesterday's 1.61% Sell Off
Comtex SmarTrend(R) - Tue Dec 23, 4:26PM CST
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $42.62 to a high of $43.31. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $42.66 on volume of 4.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GSK: 42.85 (+0.11)
GlaxoSmithKline Set to Possibly Rebound After Yesterday's Selloff of 1.61%
Comtex SmarTrend(R) - Tue Dec 23, 4:25PM CST
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $42.62 to a high of $43.31. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $42.66 on volume of 4.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GSK: 42.85 (+0.11)
BioMarin CEO Sees Big Future For Prosensa Drug
at Investor's Business Daily - Tue Dec 23, 3:11PM CST
BioMarin Pharmaceuticals raised a few eyebrows last month when it announced its latest buyout. BioMarin (BMRN) agreed to pay $680 million upfront for Prosensa Holding (RNA), a Dutch biotech developing a drug for Duchenne muscular dystrophy called...
BMRN: 88.18 (+0.89), RNA: 18.76 (+0.10), PTCT: 51.66 (+0.76), GSK: 42.85 (+0.11)
Roivant Acquires SB742457 From GlaxoSmithKline
GlobeNewswire - Tue Dec 23, 9:29AM CST
-Roivant intends to commence Phase 3 clinical trials in Alzheimer's disease in 2015-
GSK: 42.85 (+0.11)
3 Clinical Stage Biotech Stocks That Should Be on Your Watchlist in 2015
Motley Fool Staff - Motley Fool - Tue Dec 23, 6:07AM CST
Source: Celgene Corp Biotech stocks are notorious for their stratospheric gains and subterranean losses, especially clinical stage biotech stocks that develop promising, yet unproven, next-generation drugs. Those emerging biotech stocks may offer...
BLUE: 88.76 (+3.23), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), NVS: 93.91 (+0.66), CELG: 109.60 (+3.48), FPRX: 26.12 (+0.07), EXEL: 1.29 (-0.01)
Glaxo submits sNDA for Promacta expanded label
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 10:48AM CST
LGND: 51.79 (+1.22), GSK: 42.85 (+0.11)
3 Drugmakers Facing a Pivotal 2015
George Budwell, The Motley Fool - Motley Fool - Mon Dec 22, 10:41AM CST
Source: www.bio.org Pharmaceutical companies have been some of the best performing stocks lately due to the confluence of an aging U.S. population and new regulatory avenues within the Food and Drug Administration that have led to an uptick in drug...
BIIB: 340.89 (+5.13), ISIS: 59.49 (+1.88), GWPH: 68.08 (+1.82), AZN: 70.44 (+0.26), IBB: 299.80 (+5.12), PTCT: 51.66 (+0.76), GSK: 42.85 (+0.11)
Overvalued Bonds Or Would You Buy Stocks With A PE Of 100?
Seeking Early Retirement - at Seeking Alpha - Mon Dec 22, 8:31AM CST
BTI: 110.32 (+1.08), IEF: 105.25 (-0.08), COP: 70.13 (-0.92), MO: 50.36 (-0.17), GSK: 42.85 (+0.11), VOD: 34.65 (-0.05), PM: 83.15 (-0.15), T: 33.96 (-0.07), SPY: 207.77 (+0.02), RDS.A: 68.42 (-0.31), DIA: 180.03 (unch), BP: 38.95 (-0.17), SNY: 46.35 (+0.50), CVX: 113.47 (-0.48), VZ: 47.67 (unch)
Ligand Partner GlaxoSmithKline Announces US Regulatory Submission Seeking Additional Indication for Promacta(R)
Business Wire - Mon Dec 22, 8:20AM CST
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that its partner GlaxoSmithKline (GSK) plc reported the submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration for eltrombopag (Promacta), seeking an additional indication in pediatric patients six years old and older with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.
LGND: 51.79 (+1.22), GSK: 42.85 (+0.11)
The Most Disappointing Clinical Failures in 2014
Motley Fool Staff - Motley Fool - Sun Dec 21, 6:32PM CST
Since roughly 90% of all clinical trials end in a failure, it isn't too shocking that 2014 boasted its fair share of clinical trial disappointments. But while failure is common and expected in the industry, some defeats were more disappointing than...
MDVN: 99.23 (+1.23), JNJ: 104.59 (+0.31), AZN: 70.44 (+0.26), PFE: 31.42 (-0.03), AMGN: 160.67 (+3.15), GSK: 42.85 (+0.11), EXEL: 1.29 (-0.01)
Exciting News: A Game-Changing Shingles Vaccine Could Be On Its Way
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 21, 6:14AM CST
Source: GlaxoSmithKline plc GlaxoSmithKline reported late stage trial results for a promising new vaccine for the prevention of shingles that could help millions of people, and in the process win away sales from Merck & Co .'s shingles...
PFE: 31.42 (-0.03), MRK: 57.46 (+0.25), GSK: 42.85 (+0.11)
Tax-Loss Selling: 1 Stock We'd Be Glad to Sell Right Now
Motley Fool Staff - Motley Fool - Sat Dec 20, 4:05PM CST
The end of the year is a good time to unload any stocks that are sinking your portfolio. With 2014 rapidly coming to an end, many investors are selling off some of their losing investments to reap the tax benefits. Keep in mind that it's not a...
CHK: 19.84 (-0.45), GSK: 42.85 (+0.11), PSEC: 8.59 (-0.02), NVS: 93.91 (+0.66)
The Early Retiree Portfolio For 2015
Early Retiree - at Seeking Alpha - Fri Dec 19, 5:17PM CST
CBI: 41.94 (-0.17), WAIR: 14.20 (unch), VRX: 140.33 (-0.22), DVA: 76.06 (+0.07), IBM: 161.82 (-0.42), THRX: 14.55 (+0.22), TBPH: 14.84 (+0.20), GSK: 42.85 (+0.11), UG: 19.75 (-0.11)
Agenus Jumps on Positive Data from Shingles Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 3:09PM CST
Shares of Agenus Inc. (AGEN) jumped after its partner GlaxoSmithKline (GSK) announced encouraging results on HZ/su.
AGEN: 3.85 (unch), BIIB: 340.89 (+5.13), AMGN: 160.67 (+3.15), GSK: 42.85 (+0.11)
Seeking Alpha's Biotech Weekly: A Merck Purchase, Spectacular Auspex, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Dec 19, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. What should the Seeking Alpha community be reading and writing about? Please leave...
SPHS: 0.46 (+0.02), ASPX: 49.93 (-0.10), MDVN: 99.23 (+1.23), CYCC: 0.69 (+0.01), OPK: 9.63 (+0.21), NLNK: 39.08 (+1.36), JUNO: 39.99 (+2.71), REGN: 400.12 (+6.07), MYGN: 36.50 (+0.28), PFE: 31.42 (-0.03), IMGN: 5.90 (+0.13), AMGN: 160.67 (+3.15), GSK: 42.85 (+0.11), BMY: 59.15 (-0.01), BLRX: 1.68 (-0.01), OREX: 5.98 (+0.01), DVA: 76.06 (+0.07), BLCM: 19.30 (+0.18), CBST: 100.29 (-0.09), GILD: 91.29 (+1.84), GERN: 3.06 (+0.05), MRK: 57.46 (+0.25), NVS: 93.91 (+0.66)
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 340.89 (+5.13), VRX: 140.33 (-0.22), QLTI: 3.72 (+0.08), CTRX: 51.83 (+0.14), BCRX: 11.83 (+0.76), ACT: 254.20 (-1.68), MDT: 74.08 (+0.31), TKMR: 13.97 (+0.14), NEPT: 1.88 (+0.03), BSX: 13.13 (+0.07), AGN: 210.12 (+0.95), CMRX: 36.80 (+0.70), ALNY: 93.52 (+0.97), SRPT: 13.88 (+0.47), SHPG: 209.29 (+0.07), NLNK: 39.08 (+1.36), SNY: 46.35 (+0.50), MSLI: 1.67 (+0.02), NVCN: 6.60 (unch), CRME: 8.56 (+0.06), EBS: 27.64 (+1.28), GSK: 42.85 (+0.11), CELG: 109.60 (+3.48), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), NVDQ: 16.90 (+0.55), NVS: 93.91 (+0.66)
Strength Seen in Agenus (AGEN): Stock Soars 17.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 8:46AM CST
Agenus (AGEN) was a big mover last session, with shares rising over 17% on the day.
AGEN: 3.85 (unch), GSK: 42.85 (+0.11)
Factors Moving Markets: Complementary Research on GlaxoSmithKline, Cintas, Deere, Thermo Fisher and Pfizer
PR Newswire - Fri Dec 19, 8:10AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including GlaxoSmithKline (NYSE: GSK), Cintas (NASDAQ: CTAS), Deere (NYSE: DE), Thermo Fisher (NYSE: TMO), and Pfizer (NYSE: PFE). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
CTAS: 79.86 (+0.22), TMO: 126.79 (+0.13), PFE: 31.42 (-0.03), DE: 90.26 (-0.59), GSK: 42.85 (+0.11)
Acne Vulgaris - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/86w8nv/acne_vulgaris) has announced the addition of the "Acne Vulgaris - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acne Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acne Vulgaris and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acne Vulgaris - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acne Vulgaris pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Advancell - Allergan - AndroScience - AntiCancer - Ausio Pharmaceuticals - Biomar Microbial - Boehringer Ingelheim - Braintree Laboratories - Celtaxsys - Cosmo Pharmaceuticals - Cutanea Life Sciences - Delenex Therapeutics - Deltanoid Pharmaceuticals - Dermira - ELORAC - Ensoltek - Foamix - Galderma - GlaxoSmithKline - Kasiak Research - Maruho - OrigImm - Phosphagenics - Photocure - Provectus Biopharmaceuticals - RestorGenex Corporation - Thesan Pharmaceuticals - Toyama Chemical - Valeant Pharmaceuticals International - XBiotech USA - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/86...e_vulgaris
PVCT: 0.85 (-0.02), AGN: 210.12 (+0.95), GSK: 42.85 (+0.11), XOMA: 3.68 (+0.11), VRX.TO: 162.98 (-0.62)
